Trends in endocrine therapy prescription and survival in patients with non-metastatic hormone receptor positive breast cancer treated with endocrine therapy: A population based-study.

Fiche publication


Date publication

juin 2021

Journal

Breast (Edinburgh, Scotland)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr COUTANT Charles, Dr DABAKUYO-YONLI Sandrine, Dr LADOIRE Sylvain, Pr MAYNADIE Marc, Dr BILLA Oumar, Dr DESMOULINS Isabelle, Dr MAMGUEM KAMGA Ariane


Tous les auteurs :
Mamguem Kamga A, Billa O, Ladoire S, Poillot ML, Jolimoy G, Roignot P, Coutant C, Desmoulins I, Maynadie M, Dabakuyo-Yonli TS

Résumé

To identify prognostic factors of invasive-disease free survival (iDFS) in women with non-metastatic hormone receptor positive (HR+) breast cancer (BC) in daily routine practice.

Mots clés

Breast cancer, Endocrine therapy, Hormone receptor positive, Invasive disease-free survival, Non-metastatic cancer

Référence

Breast. 2021 Jun 11;59:79-86